About Cyrus Bio
Cyrus Bio is a private company based in Seattle, Washington. It has reported $37,783,582 raised in ten offerings on Form D since May 2015. Its chief executive is Lucas Nivon.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 1, 2025 | Jul 16, 2025amended May 8, 2026 | $1,481,812of $3.0M target | 17 | $87,165 | Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 29, 2024 | Dec 31, 2024 | $3,183,997of $3.5M target | 27 | $117K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Feb 27, 2024 | Feb 29, 2024 | $2,694,470of $4.0M target | 33 | $81,651 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jun 22, 2021 | Jul 7, 2021amended Dec 2, 2021 | $18,352,692of $19.3M target | 34 | $539K | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Sep 4, 2020 | Sep 17, 2020 | $1,131,000of $1.5M target | 19 | $59,526 | DebtRule 506(b) | Form D ↗ |
| Jul 13, 2017 | Jul 27, 2017 | $8,024,611of $8.0M target | 18 | $445K | EquityRule 506(b) | Form D ↗ |
| Feb 13, 2017 | Feb 21, 2017 | $1,040,000of $1.2M target | 13 | $80,000 | EquityRule 506(b) | Form D ↗ |
| Nov 7, 2016 | Nov 16, 2016 | $490,000of $500K target | 14 | $35,000 | Equity, Debt is convertible, under certain circumstances, into issuer equity.Rule 506(b) | Form D ↗ |
| Mar 23, 2016 | Apr 6, 2016 | $535,000of $575K target | 14 | $38,214 | Debt, Debt is convertible, under certain cicumstances, into issuer equity.Rule 506(b) | Form D ↗ |
| Apr 22, 2015 | May 6, 2015 | $850,000fully sold | 12 | $70,833 | DebtRule 506(b) | Form D ↗ |
| Total, ten offerings | $37,783,582 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Cyrus Bio's Form D filed May 8, 2026.
Earlier filings also listed Gus Tai (director, last listed Dec 2021), Eric Bell (director, last listed Sep 2020) and Javier Castellanos (executive officer, last listed Jul 2017).
Sources
- SECCyrus Biotechnology, Inc. Form D, filed Jul 16, 2025
- SECCyrus Biotechnology, Inc. Form D/A, filed Oct 6, 2021
- SECCyrus Biotechnology, Inc. Form D, filed Jul 7, 2021
- SECCyrus Biotechnology, Inc. filing history
- CompanyCyrus Biotechnology financial conflict of interest policy
- CompanyCyrus Bio news
- CompanyCyrus Bio leadership